Literature DB >> 10554014

Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines.

F G Barr1, J C Fitzgerald, J P Ginsberg, M L Vanella, R J Davis, J L Bennicelli.   

Abstract

PAX3 and PAX7 are closely related paired box family members expressed during early neural and myogenic development. Assay of PAX3 and PAX7 mRNA expression in embryonal rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma, and melanoma cell lines revealed tumor-specific expression patterns similar to the corresponding embryonic lineages. Although the mammalian PAX3 and PAX7 genes were reported to contain eight exons, we found that the predominant PAX3 and PAX7 transcripts in these tumor lines contain previously uncharacterized ninth exons. These splicing events alter the COOH-terminal coding regions of the encoded products but do not alter the transcriptional activity as assayed using a reporter gene with a model PAX3/PAX7 binding site. However, the findings of nearly identical COOH-terminal regions within the corresponding genes of the avian and fish genomes suggest conserved functional roles for these regions that require further investigation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554014

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.

Authors:  Lydie Pani; Melissa Horal; Mary R Loeken
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

2.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

3.  Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis.

Authors:  Elizabeth Charytonowicz; Igor Matushansky; Mireia Castillo-Martin; Todd Hricik; Carlos Cordon-Cardo; Mel Ziman
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

4.  The evolution of alternative splicing in the Pax family: the view from the Basal chordate amphioxus.

Authors:  Stephen Short; Linda Z Holland
Journal:  J Mol Evol       Date:  2008-05-14       Impact factor: 2.395

5.  TBX2 expression is regulated by PAX3 in the melanocyte lineage.

Authors:  Fang Liu; Juxiang Cao; Jinghu Lv; Liang Dong; Eric Pier; George X Xu; Rui-an Wang; Zhixiang Xu; Colin Goding; Rutao Cui
Journal:  Pigment Cell Melanoma Res       Date:  2012-11-21       Impact factor: 4.693

6.  Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.

Authors:  Irina Berlin; Laurence Denat; Anne-Lise Steunou; Isabel Puig; Delphine Champeval; Sophie Colombo; Karen Roberts; Elise Bonvin; Yveline Bourgeois; Irwin Davidson; Véronique Delmas; Laurence Nieto; Colin R Goding; Lionel Larue
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

7.  Clinical significance and prognostic value of PAX3 expression in human glioma.

Authors:  Jian Chen; Liang Xia; Xiujie Wu; Liqin Xu; Dekang Nie; Jinlong Shi; Xide Xu; Lanchun Ni; Shaoqing Ju; Xinhua Wu; Hui Zhu; Wei Shi
Journal:  J Mol Neurosci       Date:  2012-01-10       Impact factor: 3.444

Review 8.  Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.

Authors:  Jennifer D Kubic; Kacey P Young; Rebecca S Plummer; Anton E Ludvik; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2008-12       Impact factor: 4.693

9.  PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).

Authors:  Sandra Medic; Mel Ziman
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

10.  RBM4 promotes pancreas cell differentiation and insulin expression.

Authors:  Jung-Chun Lin; Yu-Ting Yan; Wen-Kou Hsieh; Pey-Jey Peng; Chun-Hao Su; Woan-Yuh Tarn
Journal:  Mol Cell Biol       Date:  2012-11-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.